RESEARCH TRIANGLE PARK, NC, February 2, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced that Chief Executive Officer Mark Velleca, MD, PhD, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9 at 9:45 a.m. ET at the Waldorf Astoria in New York City.

For additional information on the conference, visit: https://www.bio.org/events/conferences/bio-ceo-investor-conference. 

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates that address two markets:  CDK4/6 antineoplastics and protection of the bone marrow from damage by chemotherapy (chemoprotection). The company's lead program, G1T28, is a highly potent and selective CDK4/6 inhibitor that is currently being evaluated in Phase 1a clinical trials.

Visit www.g1therapeutics.com for more information.

###

Contact:                                                              
Mark Velleca, MD, PhD                
G1 Therapeutics                                              
919-213-9838                                                    
mvelleca@g1therapeutics.com                  

Media:
Laura Bagby                       
6 Degrees Communications
312-448-8098 
lbagby@6degreespr.com